Restoration of p53 to limit tumor growth

Current Opinion in Oncology

Volumn 20, Issue 1, 2008, Pages 90-96

  Wang, Wenge ^a   El Deiry, Wafik S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acridine derivatives; Carboline derivatives; CP 31398; Nutlins; p53; p63; p73; PRIMA 1; Transcriptional activation

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; DOXORUBICIN; ELLIPTICINE; IMIDAZOLINE DERIVATIVE; NUTLIN; PRIMA 1; PROTEIN MDM2; PROTEIN P53; PROTEIN P63; PROTEIN P73; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER GENE THERAPY; CANCER INHIBITION; CELL DEATH; COLON CARCINOMA; DRUG TARGETING; HUMAN; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL CYCLE; ELLIPTICINES; GENES, P53; HUMANS; IMIDAZOLES; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PIPERAZINES; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36549009637     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f31d6f     Document Type: Review

References (68)

1. El-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8:345-357.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-310.
3. Li M, Brooks CL, Wu-Baer F, et al. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003; 302:1972-1975.
4. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378:203-206.
5. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378:206-208.
6. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004; 429:86-92.
7. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003; 112:779-791.
8. Tang J, Qu LK, Zhang J, et al. Critical role for Daxx in regulating Mdm2. Nat Cell Biol 2006; 8:855-862. Daxx, a death domain-associated protein, was shown to stabilize Mdm2. Downregulation of Daxx decreases Mdm2 levels, whereas overexpression of Daxx strongly stabilizes Mdm2. Daxx simultaneously binds to Mdm2 and the deubiquitinase Hausp, and it mediates the stabilizing effect of Hausp on Mdm2. In addition, Daxx enhances the intrinsic E3 activity of Mdm2 towards p53.
9. Li L, Deng B, Xing G, et al. PACT is a negative regulator of p53 and essential for cell growth and embryonic development. Proc Natl Acad Sci USA 2007; 104:7951-7956. PACT can interact with Hdm2 and enhance Hdm2-mediated ubiquitination and degradation of p53 as a result of the increase of the p53-Hdm2 affinity. Consequently, PACT represses p53-dependent gene transcription. Knockdown of PACT significantly attenuates the p53-Hdm2 interaction, reduces p53 poly-ubiquitination, and enhances p53 accumulation, leading to both apoptosis and retardation of cell growth.
10. Yang W, Rozan LM, McDonald ER 3rd, et al. CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem 2007; 282:3273-3281.
11. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci USA 1995; 92:2563-2567.
12. Huang L, Kinnucan E, Wang G, et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 1999; 286:1321-1326.
13. Li Z, Day CP, Yang JY, et al. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res 2004; 64:9080-9085.
14. Yew PR, Liu X, Berk AJ. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev 1994; 8:190-202.
15. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22:3551-3555.
16. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998; 292:435-445.
17. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001; 8:1066-1075.
18. McDonald ER 3rd, El-Deiry WS. Cell cycle control as a basis for cancer drug development. Int J Oncol 2000; 16:871-886.
19. Gabrilovich DI. INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther 2006; 6:823-832.
20. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-848.
21. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13:23-31.
22. Selivanova G, Iotsova V, Okan I, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997; 3:632-638.
23. Selivanova G, Ryabchenko L, Jansson E, et al. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol 1999; 19:3395-3402.
24. Kanovsky M, Raffo A, Drew L, et al. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci USA 2001; 98:12438-12443.
25. Do TN, Rosal RV, Drew L, et al. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene 2003; 22:1431-1444.
26. Friedler A, Hansson LO, Veprintsev DB, et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 2002; 99:937-942.
27. Midgley CA, Desterro JM, Saville MK, et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000; 19:2312-2323.
28. Wang W, El-Deiry WS. Targeting p53 by PTD-mediated transduction. Trends Biotechnol 2004; 22:431-434.
29. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004; 2:E36.
30. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10:310-315.
31. Brown CR, Hong-Brown LQ, Welch WJ. Correcting temperature-sensitive protein folding defects. J Clin Invest 1997; 99:1432-1444.
32. Wolkowicz R, Rotter V. The DNA binding regulatory domain of p53: see the C. Pathol Biol (Paris) 1997; 45:785-796.
33. Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG. Reactivation of mutant p53: a new strategy for cancer therapy. Semin Cancer Biol 1998; 8:369-378.
34. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286:2507-2510.
35. Takimoto R, Wang W, Dicker DT, et al. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002; 1:47-55.
36. Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003; 23:2171-2181.
37. Rippin TM, Bykov VJ, Freund SM, et al. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002; 21:2119-2129.
38. Halazonetis TD, Davis LJ, Kandil AN. Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. EMBO J 1993; 12:1021-1028.
39. Herbert BS, Pearce VP, Hynan LS, et al. A peroxisome proliferator-activated receptor-gamma agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells. Cancer Res 2003; 63:1914-1919.
40. Luu Y, Bush J, Cheung KJ Jr, Li G. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell Res 2002; 276:214-222.
41. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8:282-288.
42. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002; 23:2011-2018.
43. Garbett NC, Graves DE. Extending nature's leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents 2004; 4:149-172.
44. Shi LM, Myers TG, Fan Y, et al. Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol Pharmacol 1998; 53:241-251.
45. Peng Y, Li C, Chen L, et al. Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003; 22:4478-4487.
46. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90:809-819.
47. Arrowsmith CH. Structure and function in the p53 family. Cell Death Differ 1999; 6:1169-1173.
48. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25:47-54.
49. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002; 18:90-95.
50. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305-316.
51. Lohrum MA, Vousden KH. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol 2000; 10:197-202.
52. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 2001; 12:337-349.
53. Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363-373.
54. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-713.
55. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-718.
56. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404:99-103.
57. White E, Prives C. DNA damage enables p73. Nature 1999; 399:734-735.
58. Irwin MS, Kondo K, Marin MC, et al. Chemosensitivity linked to p73 function. Cancer Cell 2003; 3:403-410.
59. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3:387-402.
60. Soussi T. p53 mutations and resistance to chemotherapy: a stab in the back for p73. Cancer Cell 2003; 3:303-305.
61. Liefer KM, Koster MI, Wang XJ, et al. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000; 60:4016-4020.
62. Zaika AI, Kovalev S, Marchenko ND, Moll UM. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 1999; 59:3257-3263.
63. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001; 1:233-240.
64. Bensaad K, Le Bras M, Unsal K, et al. Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73. J Biol Chem 2003; 278:10546-10555.
65. Wang W, Ho WC, Dicker DT, et al. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther 2005; 4:893-898.
66. Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 2006; 103:11003-11008. A number of small molecules were isolated that activate p53 reporter activity, increase expression of p53 target genes, such as p21(WAF1) or death receptor 5 (KILLER/DR5) of TRAIL, and induce apoptosis in p53 wild-type as well as p53-deficient tumor cells. Some of the compounds activate a p53 response by increasing p73 expression.
67. Wiman KG. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Adv Cancer Res 2007; 97:321-338.
68. Bell HS, Dufes C, O'Prey J, et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 2007; 117:1008-1018.